BiotechTube
Agastiya Biotech

Agastiya Biotech

Cambridge, United States· Est.
agastiyabiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Agastiya Biotech is an early-stage, private biotech focused on developing novel small molecule oncology therapeutics through a unique platform combining AI, quantum biology, and ancient medical knowledge. Its lead candidate, AB001, has completed a Phase I trial showing promising efficacy and a strong safety profile, with Phase II trials now underway in India. The company's ambitious strategy targets high-value areas like pan-KRAS inhibition and cancer stem cell eradication with a single oral agent, positioning it in a competitive but potentially lucrative oncology market. Its success hinges on validating its novel mechanisms and advancing clinical development.

Oncology

Technology Platform

Proprietary P-AGI (Pillai Accelerated General Intelligence) platform, described as a fusion of quantum biology (femtomedicine), artificial intelligence, and ancient medical knowledge to accelerate molecular discovery.

Opportunities

AB001 addresses a massive unmet need in oncology through its tumor-agnostic, pan-KRAS targeting approach combined with immuno-modulation and cancer stem cell eradication.
If clinically validated, it could capture significant market share across multiple high-value cancer indications.
The oral formulation and reported safety profile offer potential differentiation and patient convenience.

Risk Factors

The primary risks are scientific validation of its novel, multi-mechanism action and unproven quantum biology foundation.
The company faces clinical development risk moving from small, open-label studies to controlled trials, operational risk due to an undisclosed management team and funding, and intense competition in the KRAS and IO therapeutic spaces.

Competitive Landscape

Agastiya competes in the highly competitive oncology space, directly with approved KRAS G12C inhibitors (e.g., sotorasib, adagrasib) and numerous PD-(L)1 inhibitors. Its pan-KRAS ambition pits it against other companies developing broader KRAS inhibitors. Its unique combination approach is its differentiator, but it faces well-funded, established players with extensive clinical and commercial experience.

More companies in Small Molecule Drugs →More companies in United States →